top of page

BF LOGO_edited.png

100834_2.3.1_Gibco_Level-1_728x90_Biofocus.gif

external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus.
Explore the latest updates from the life science industry.

Popular Content.

PHARMA

2025: A Year of Promise in Pharma and Biotech — Key Trials and Drug Candidates to Watch

The BioFocus Editorial Team recap key developments from 2024 and highlight some of the most promising clinical trials and emerging therapies to keep an eye on.

Featured Articles.

BIOTECH

The Four Powerhouses of DNA Sequencing

BIOTECH

Asimov and Revopsis Therapeutics Enter Strategic Licensing Agreement to Advance Gene Therapy Solutions

BIOTECH

Biotechnology in Agriculture - Feeding the World's Growing Population

BIOTECH

Astellas and Avexis Collaborate on Gene Therapy for Spinal Muscular Atrophy

BIOTECH

AbbVie Expands Immunology Pipeline with Acquisition of Nimble Therapeutics and Aliada Therapeutics

BIOTECH

The Future of Gene Editing Beyond CRISPR

PHARMA

Merck Partners with Hansoh Pharma on Oral GLP-1 Receptor Agonist for Diabetes

SPONSORED

Teeing up for success:
Keep your cell therapy quality goals on course

SPONSORED

CHO Playbook: Gibco™ CHO Cell Culture Solutions for Biomanufacturing

Screenshot 2024-05-31 at 16.38.09.png

Latest News.

10th January, 2025

01.

Verdiva Bio Launches with $411M Funding to Revolutionize Obesity and Cardiometabolic Care

Biotech Startup Unveils Next-Generation Therapies, Including a Promising Once-Weekly Oral GLP-1 Peptide, Backed by Leading Global Investors.

09th January, 2025

02.

IGM Biosciences Halts Lead Autoimmune Programs, Cuts Workforce by 73%

IGM Biosciences is discontinuing its lead autoimmune programs, imvotamab and IGM-2644, following disappointing clinical results, and implementing a 73% workforce reduction while reevaluating its direction.

05th January, 2025

03.

Novartis' Intrathecal Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint

Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements.

03rd January, 2025

04.

GSK’s Nucala Approved in China for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps

GSK’s Nucala has been approved by China’s National Medical Products Administration for the treatment of adults with chronic rhinosinusitis with nasal polyps, offering a new therapeutic option for patients.

Editor's Selects.

Essential Strategies for Scaling Up Biologics

Biotechnology in Agriculture - Feeding the World’s Growing Population

Researchers Secure £3.9M Grant to Explore Early Axonal Dysfunction in ALS and FTD

The 2024 Nobel Prize in Physiology or Medicine Winners

Event Spotlight.

Explore the key upcoming industry events.

Discover more.

Stay up-to-date. Connect with BioFocus on LinkedIn or subscribe to our mailing list.

bottom of page